Top

03-05-2017 | Gout | Article

Risk of infections in patients with gout: a population-based cohort study

Journal: Scientific Reports

Authors: B. Spaetgens, F. de Vries, J. H. M. Driessen, H. G. Leufkens, P. C. Souverein, A. Boonen, J. W. M. van der Meer, L. A. B. Joosten

Publisher: Nature Publishing Group UK

Abstract

To investigate the risk of various types of infections (pneumonia and urinary tract infection (UTI)), and infection-related mortality in patients with gout compared with population-based controls. A retrospective cohort study was conducted using data from the UK Clinical Practice Research Datalink (CPRD). All patients with a first diagnosis of gout and aged >40 years between January 1987-July 2014, were included and matched with up to two controls. Time-varying Cox proportional hazards models were used to estimate the risk of infections and mortality. 131,565 patients and 252,763 controls (mean age: 64 years, 74% males, mean follow-up of 6.7 years) were included in the full cohort. After full statistical adjustment, the risk of pneumonia was increased (adj. HR 1.27, 95% CI 1.18 to 1.36), while the risk of UTI (adj. HR 0.99, 95% CI 0.97 to 1.01) was similar in patients compared to controls. No differences between patients and controls were observed for infection-related mortality due to pneumonia (adj. HR 1.03, 95% CI 0.93 to 1.14) or UTI (adj. HR 1.16, 95% CI 0.98 to 1.37). In conclusion, patients with gout did not have decreased risks of pneumonia, UTI or infection-related mortality compared to population-based controls.

Wijnands, J. M. et al. Determinants of the prevalence of gout in the general population: a systematic review and meta-regression. Eur J Epidemiol. 30, 19–33, doi:10.1007/s10654-014-9927-y (2015).CrossRefPubMed

Kuo, C. F., Grainge, M. J., Mallen, C., Zhang, W. & Doherty, M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 74, 661–667, doi:10.1136/annrheumdis-2013-204463 (2015).CrossRefPubMed

Zhu, Y., Pandya, B. J. & Choi, H. K. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 63, 3136–3141, doi:10.1002/art.30520 (2011).CrossRefPubMed

Richette, P. & Bardin, T. Gout. Lancet. 375, 318–328, doi:10.1016/S0140-6736(09)60883-7 (2010).CrossRefPubMed

Robinson, P. C., Merriman, T. R., Herbison, P. & Highton, J. Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999–2009. Rheumatology (Oxford) 52, 118–126, doi:10.1093/rheumatology/kes253 (2013).CrossRef

Stamp, L. K. & Chapman, P. T. Gout and its comorbidities: implications for therapy. Rheumatology (Oxford). 52, 34–44, doi:10.1093/rheumatology/kes211 (2013).CrossRefPubMed

McCarthy, D. J. & Hollander, J. L. Identification of urate crystals in gouty synovial fluid. Ann Intern Med. 54, 52–60 (1961).

Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 440, 237–241, doi:10.1038/nature04516 (2006).ADSCrossRefPubMed

Chen, C. J. et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest. 116, 2262–2271, doi:10.1172/JCI28075 (2006).CrossRefPubMedPubMedCentral

10.

Liu-Bryan, R. Intracellular innate immunity in gouty arthritis: role of NALP3 inflammasome. Immunol Cell Biol. 88, 20–23, doi:10.1038/icb.2009.93 (2010).CrossRefPubMed

11.

Dalbeth, N. et al. Cellular characterization of the gouty tophus: a quantitative analysis. Arthritis Rheum 62, 1549–1556, doi:10.1002/art.27356 (2010).CrossRefPubMed

12.

Mylona, E. E. et al. Enhanced interleukin-1beta production of PBMCs from patients with gout after stimulation with Toll-like receptor-2 ligands and urate crystals. Arthritis Res Ther. 14, R158, doi:10.1186/ar3898 (2012).CrossRefPubMedPubMedCentral

13.

Netea, M. G., Quintin, J. & van der Meer, J. W. Trained immunity: a memory for innate host defense. Cell Host Microbe 9, 355–361, doi:10.1016/j.chom.2011.04.006 (2011).CrossRefPubMed

14.

Crisan, T. O. et al. Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra. Ann Rheum Dis. 75, 755–762, doi:10.1136/annrheumdis-2014-206564 (2016).CrossRefPubMed

15.

Dinarello, C. A. Biologic basis for interleukin-1 in disease. Blood. 87, 2095–2147 (1996).PubMed

16.

Herrett, E., Thomas, S. L., Schoonen, W. M., Smeeth, L. & Hall, A. J. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol. 69, 4–14, doi:10.1111/j.1365-2125.2009.03537.x (2010).CrossRefPubMedPubMedCentral

17.

Wijnands, J. M. et al. Individuals With Type 2 Diabetes Mellitus Are at an Increased Risk of Gout But This Is Not Due to Diabetes: A Population-Based Cohort Study. Medicine (Baltimore). 94, e1358, doi:10.1097/MD.0000000000001358 (2015).CrossRefPubMedPubMedCentral

18.

van der Zanden, R. et al. Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study. PLoS One. 10, e0139367, doi:10.1371/journal.pone.0139367 (2015).CrossRef

19.

Herrett, E. et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 44, 827–836, doi:10.1093/ije/dyv098 (2015).CrossRefPubMedPubMedCentral

20.

Gallagher, A. M., Williams, T., Leufkens, H. G. & de Vries, F. The Impact of the Choice of Data Source in Record Linkage Studies Estimating Mortality in Venous Thromboembolism. PLoS One. 11, e0148349, doi:10.1371/journal.pone.0148349 (2016).CrossRefPubMedPubMedCentral

21.

Lim, S. Y., Lu, N. & Choi, H. K. Septic arthritis in gout patients: a population-based cohort study. Rheumatology (Oxford). 54, 2095–2099, doi:10.1093/rheumatology/kev236 (2015).CrossRefPubMed

22.

Netea, M. G. et al. Trained immunity: A program of innate immune memory in health and disease. Science. 352, aaf1098–aaf1098, doi:10.1126/science.aaf1098 (2016).CrossRefPubMedPubMedCentral

23.

Kleinnijenhuis, J. et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci USA 109, 17537–17542, doi:10.1073/pnas.1202870109 (2012).ADSCrossRefPubMedPubMedCentral

24.

Crisan, T. O., Netea, M. G. & Joosten, L. A. Innate immune memory: Implications for host responses to damage-associated molecular patterns. Eur J Immunol. 46, 817–828, doi:10.1002/eji.201545497 (2016).CrossRefPubMed

25.

De Vera, M. A., Marcotte, G., Rai, S., Galo, J. S. & Bhole, V. Medication adherence in gout: a systematic review. Arthritis Care Res (Hoboken) 66, 1551–1559, doi:10.1002/acr.v66.10 (2014).CrossRef

26.

Katz, R., Chuang, L. C. & Sutton, J. D. Use of granulocyte colony-stimulating factor in the treatment of pancytopenia secondary to colchicine overdose. Ann Pharmacother. 26, 1087–1088, doi:10.1177/106002809202600907 (2014).CrossRef

27.

Critchley, J. A., Critchley, L. A. & Yeung, E. A. et al. Granulocyte-colony stimulating factor in the treatment of colchicine poisoning. Hum Exp Toxicol. 16, 229–232, doi:10.1177/096032719701600413 (1997).CrossRefPubMed

28.

Ben-Chetrit, E. & Navon, P. Colchicine-induced leukopenia in a patient with familial Mediterranean fever: the cause and a possible approach. Clin Exp Rheumatol. 21 (4 Suppl 30), S38–40 (2003).PubMed

29.

Kocak, Z., Akay, H., Gucenmez, S., Tufan, A. & Donderici, O. Colchicine intoxication and infection risk: a case report. J Clin Pharm Ther 33, 451–452, doi:10.1111/jcp.2008.33.issue-4 (2008).CrossRefPubMed

30.

Malawista, S. E. & Bodel, P. T. The dissociation by colchicine of phagocytosis from increased oxygen consumption in human leukocytes. J Clin Invest. 46, 786–796, doi:10.1172/JCI105579 (1967).CrossRefPubMedPubMedCentral

31.

Rinehart, J. J. & Boulware, T. Microfilament and microtubule function in human monocytes. J Lab Clin Med. 90, 737–743 (1977).PubMed

32.

Kuo, C. F. et al. Elevated risk of mortality among gout patients: a comparison with the national population in Taiwan. Joint Bone Spine 78, 577–580, doi:10.1016/j.jbspin.2011.01.007 (2011).CrossRefPubMed

33.

Kuo, C. F. et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford). 49, 141–146, doi:10.1093/rheumatology/kep364 (2010).CrossRefPubMed

34.

Smeeth, L. et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 351, 2611–2618, doi:10.1056/NEJMoa041747 (2004).CrossRefPubMed

35.

Khan, N. F., Harrison, S. E. & Rose, P. W. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract. 60, e128–e136, doi:10.3399/bjgp10X483562 (2010).CrossRefPubMedPubMedCentral

Medicine Matters Rheumatology

Abstract